Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>The minerals exploration and development Company announced that GreenTech Metals Limited, an Australian listed business, in which Alien holds a stake of approximately 10%, has reported exceptional high-grade copper-gold-silver-zinc assay results from diamond drilling at its 100%-owned Whundo project in Western Australia.</li>
<li>The drilling was at the Ayshia deposit, and it was notable for the inclusion of a 3.44 metre intersection grading 9.43% copper - the highest-average-grade multi-metre copper intersection identified at Ayshia to date and one of the highest-grade copper intersections recorded across the broader Whundo Project.</li>
<li>The exploration program is designed to add to the existing Whundo mineral resource of 6.2m tonnes at 1.12% copper, and 1.04% zinc, with an updated Mineral Resource Estimate targeted for Q4 2026.</li>
</ul>


The minerals exploration and development Company announced that GreenTech Metals Limited, an Australian listed business, in which Alien holds a stake of approximately 10%, has reported exceptional high-grade copper-gold-silver-zinc assay results from diamond drilling at its 100%-owned Whundo project in Western Australia.
The drilling was at the Ayshia deposit, and it was notable for the inclusion of a 3.44 metre intersection grading 9.43% copper - the highest-average-grade multi-metre copper intersection identified at Ayshia to date and one of the highest-grade copper intersections recorded across the broader Whundo Project.
The exploration program is designed to add to the existing Whundo mineral resource of 6.2m tonnes at 1.12% copper, and 1.04% zinc, with an updated Mineral Resource Estimate targeted for Q4 2026.


Tribal Group plc - Hybridan Small Cap Feast: 14 September 2026

Research from Hardman & Co, Hardman & Co

Hardman & Co

Research from Hardman & Co

Investment research on quoted companies and funds

Hardman & Co is a multi-disciplinary financial consultancy and investment research firm, employing highly experienced analysts and professionals with a broad range of capital markets expertise. Our clients are public and private businesses as well as fund managers, ranging from start-ups to £1 billion+ market capitalisations. Hardman & Co offers corporate research & consultancy, serving the needs of both public and private companies. We produce gold-standard research with a global reach for trading and investment companies, as well as providing market commentary and analysis. In addition, we carry out a number of bespoke investment-related assignments, including due diligence on bond listings, assessments of private company valuations and other corporate advisory services. We engage with the market through traditional and digital media, offering illuminating video content on corporate management strategy, results communication, interviews and in-house sector discussion.

Thematic (Sector/Industry)

<ul>
<li>The Hardman &amp; Co Healthcare Index (HHI) has been running since 2009.</li>
<li>Its main function is to highlight the attractions of life sciences investments over the long term.</li>
<li>For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector.</li>
</ul>


The Hardman &amp; Co Healthcare Index (HHI) has been running since 2009.
Its main function is to highlight the attractions of life sciences investments over the long term.
For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector.


Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences

Conroy Gold & Natural Resources / Equity Bottom-Up

Conroy Gold & Natural Resources (CGNR LN)

<ul>
<li>80 Mile 0.92p £46.15m (80M.L) The exploration and development Company with projects in Greenland, Finland and Italy, announced an update on recent developments at Disko-Nuussuaq nickel-copper-cobalt-PGE project in West Greenland, and the 2026 drill season.</li>
<li>The Company will operate two diamond drill rigs at Disko for the 2026 season and further advise that in consultation with the joint venture partner, USFM Corporation who is spending US$30m for 51% over 3 years, that the 2026 drilling programme has been expanded from 5,000m to 9,000m.</li>
<li>CelLBxHealth 1.55p £19.94m (CLBX.L) The CTC intelligence Company specialising in innovative circulating tumour cell (CTC) solutions announced its audited preliminary results for the year ending 31 December 2025. </li>
</ul>


80 Mile 0.92p £46.15m (80M.L) The exploration and development Company with projects in Greenland, Finland and Italy, announced an update on recent developments at Disko-Nuussuaq nickel-copper-cobalt-PGE project in West Greenland, and the 2026 drill season.
The Company will operate two diamond drill rigs at Disko for the 2026 season and further advise that in consultation with the joint venture partner, USFM Corporation who is spending US$30m for 51% over 3 years, that the 2026 drilling programme has been expanded from 5,000m to 9,000m.
CelLBxHealth 1.55p £19.94m (CLBX.L) The CTC intelligence Company specialising in innovative circulating tumour cell (CTC) solutions announced its audited preliminary results for the year ending 31 December 2025. 


<ul>
<li>The alternative energy Company announced further to the Company's announcement dated 20 April 2026 regarding the energisation of the Ghummud site, it has redeployed digital infrastructure originally procured for its 8 Mega Volt Ampere (MVA) development site in the United Arab Emirates to the Ghummud facility, enabling immediate utilisation and accelerated revenue generation.</li>
<li>Once at maximum capacity, the Ghummud site will be capable of generating annualised hosting revenue of $400,000 per MVA per annum.</li>
<li>The Board anticipates this will be achieved within the next six weeks.</li>
</ul>


The alternative energy Company announced further to the Company's announcement dated 20 April 2026 regarding the energisation of the Ghummud site, it has redeployed digital infrastructure originally procured for its 8 Mega Volt Ampere (MVA) development site in the United Arab Emirates to the Ghummud facility, enabling immediate utilisation and accelerated revenue generation.
Once at maximum capacity, the Ghummud site will be capable of generating annualised hosting revenue of $400,000 per MVA per annum.
The Board anticipates this will be achieved within the next six weeks.


<ul>
<li>The mid-market, challenger professional services platform and owner of the Dow Schofield Watts and the DR Solicitors brands reported strong revenue and EBITDA growth in its Interims to September.</li>
<li>Revenue improved from £1.1m to £2.2m with EBITDA up from £0.1m to £0.7m.</li>
<li>The cash balances of £2.2m is allowing an interim dividend of 1.2p per share to be paid to shareholders on the register on 12 December. </li>
</ul>


The mid-market, challenger professional services platform and owner of the Dow Schofield Watts and the DR Solicitors brands reported strong revenue and EBITDA growth in its Interims to September.
Revenue improved from £1.1m to £2.2m with EBITDA up from £0.1m to £0.7m.
The cash balances of £2.2m is allowing an interim dividend of 1.2p per share to be paid to shareholders on the register on 12 December. 


Trellus Health Plc - Hybridan Small Cap Feast: 24 November 2025

United Kingdom

Fusion Antibodies is a Collaborative Research Organisation (CRO) specializing in antibody discovery, engineering, and supply. The company offers a range of services including antibody generation, development, production, characterization, and optimization for therapeutic drug and diagnostic applications. Fusion Antibodies is headquartered in Belfast, United Kingdom, and was established in 2001.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Fusion Antibodies (FAB LN)

Tribal Group plc - Hybridan Small Cap Feast: 14 September 2026

The exploration program is designed to add to the existing Whundo mineral resource of 6.2m tonnes at 1.12% copper, and 1.04% zinc, with an updated...

Hybridan

Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments...

Hardman & Co

Hybridan Small Cap Feast: 22 June 2026

The CTC intelligence Company specialising in innovative circulating tumour cell (CTC) solutions announced its audited preliminary results for the...

Hybridan

Hybridan Small Cap Feast: 5 May 2026

Once at maximum capacity, the Ghummud site will be capable of generating annualised hosting revenue of $400,000 per MVA per annum.

Hybridan

Trellus Health Plc - Hybridan Small Cap Feast: 24 November 2025

The mid-market, challenger professional services platform and owner of the Dow Schofield Watts and the DR Solicitors brands reported strong revenue...

Hybridan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)